GraniteShares Advisors LLC Sells 331 Shares of Eli Lilly and Company (NYSE:LLY)

GraniteShares Advisors LLC decreased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 9.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,131 shares of the company’s stock after selling 331 shares during the quarter. GraniteShares Advisors LLC’s holdings in Eli Lilly and Company were worth $2,586,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also bought and sold shares of the company. Knightsbridge Asset Management LLC raised its holdings in Eli Lilly and Company by 1.9% during the 4th quarter. Knightsbridge Asset Management LLC now owns 813 shares of the company’s stock valued at $628,000 after acquiring an additional 15 shares during the period. Centerpoint Advisory Group bought a new stake in Eli Lilly and Company during the 4th quarter valued at $514,000. LS Investment Advisors LLC raised its holdings in Eli Lilly and Company by 1.7% during the 1st quarter. LS Investment Advisors LLC now owns 2,340 shares of the company’s stock valued at $1,933,000 after acquiring an additional 40 shares during the period. Kentucky Trust Co bought a new stake in Eli Lilly and Company during the 4th quarter valued at $834,000. Finally, CSM Advisors LLC grew its position in shares of Eli Lilly and Company by 30.6% during the 4th quarter. CSM Advisors LLC now owns 1,045 shares of the company’s stock valued at $807,000 after purchasing an additional 245 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Up 0.4%

Shares of NYSE:LLY opened at $811.62 on Friday. The stock’s 50-day moving average price is $773.53 and its 200-day moving average price is $801.30. Eli Lilly and Company has a 12-month low of $677.09 and a 12-month high of $972.53. The stock has a market capitalization of $769.20 billion, a P/E ratio of 69.31, a price-to-earnings-growth ratio of 1.40 and a beta of 0.41. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The company had revenue of $12.73 billion for the quarter, compared to the consensus estimate of $12.77 billion. During the same period last year, the business posted $2.58 earnings per share. The firm’s quarterly revenue was up 45.2% compared to the same quarter last year. On average, equities analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th were issued a dividend of $1.50 per share. The ex-dividend date of this dividend was Friday, May 16th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.74%. Eli Lilly and Company’s dividend payout ratio is currently 48.82%.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on LLY shares. Cantor Fitzgerald started coverage on shares of Eli Lilly and Company in a research report on Tuesday, April 22nd. They set an “overweight” rating and a $975.00 price target for the company. Erste Group Bank lowered shares of Eli Lilly and Company from a “buy” rating to a “hold” rating in a research report on Thursday, June 5th. UBS Group reduced their price target on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set a “buy” rating for the company in a research report on Friday, May 2nd. Morgan Stanley restated an “overweight” rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. Finally, Hsbc Global Res lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a research report on Monday, April 28th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and eighteen have issued a buy rating to the company. Based on data from MarketBeat, Eli Lilly and Company has a consensus rating of “Moderate Buy” and a consensus target price of $1,011.37.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.